References

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

10.1038/leu.2015.356 · 2016 · External reference

10.1038/s41408-020-0311-8

10.1038/s41408-020-0311-8 · 2020 · External reference

Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma

10.1200/jco.2017.76.5032 · 2018 · External reference

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

10.1016/s1470-2045(21)00128-5 · 2021 · External reference

Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial

10.1200/jco.21.02815 · 2023 · External reference

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

10.1182/blood-2011-11-395749 · 2012 · External reference

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

10.1182/blood.2020005288 · 2020 · External reference

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

10.1016/s0140-6736(19)31240-1 · 2019 · External reference

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

10.1016/s2352-3026(23)00217-x · 2023 · External reference

Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

10.1056/nejmoa2312054 · 2023 · External reference

Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma

10.1016/j.clml.2018.01.006 · 2018 · External reference

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

10.1016/s1470-2045(13)70380-2 · 2013 · External reference

Pomalidomide

10.1182/blood-2013-05-484782 · 2013 · External reference

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

10.1200/jco.2009.23.6802 · 2009 · External reference

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

10.1038/bcj.2015.60 · 2015 · External reference

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

10.1002/ajh.26361 · 2021 · External reference

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

10.1038/s41375-018-0038-8 · 2018 · External reference

Clarithromycin synergistically enhances thalidomide cytotoxicity in myeloma cells

10.1159/000438855 · 2016 · External reference

Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy

10.1016/s0091-6749(99)70175-2 · 1999 · External reference

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

10.1182/blood-2012-08-448563 · 2013 · External reference

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma

10.1182/bloodadvances.2018028027 · 2019 · External reference

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

10.1016/s1470-2045(16)30206-6 · 2016 · External reference

Elotuzumab therapy for relapsed or refractory multiple myeloma

10.1056/nejmoa1505654 · 2015 · External reference

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

10.1182/blood-2017-05-785246 · 2017 · External reference

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

10.1056/nejmoa2303379 · 2023 · External reference

Ide-cel or standard regimens in relapsed and refractory multiple myeloma

10.1056/nejmoa2213614 · 2023 · External reference

Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma

10.1056/nejmoa2204591 · 2022 · External reference

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

10.1038/s41591-023-02528-9 · 2023 · External reference

Teclistamab in relapsed or refractory multiple myeloma

10.1056/nejmoa2203478 · 2022 · External reference

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

10.1038/s41408-021-00490-8 · 2021 · External reference

Human CD56bright NK cells: an update

10.4049/jimmunol.1502570 · 2016 · External reference

A phase I study of the combination of rituximab and ipilimumab in patients with relapsed/refractory B-cell lymphoma

10.1158/1078-0432.ccr-19-0438 · 2019 · External reference

Long-term follow-up and correlative analysis of two phase II trials of rituximab and lenalidomide followed by continuous lenalidomide in untreated and relapsed/refractory indolent lymphoma

10.1158/1078-0432.ccr-20-4622 · 2021 · External reference

Memory CD8+ T cell responses to cancer

10.1016/j.smim.2020.101435 · 2020 · External reference

The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application

10.3389/fimmu.2022.956090 · 2022 · External reference

The role of TIM-3 and LAG-3 in the microenvironment and immunotherapy of ovarian cancer

10.3390/biomedicines10112826 · 2022 · External reference

New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors

10.1007/s11912-022-01218-y · 2022 · External reference

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma

10.3389/fonc.2022.1014904 · 2022 · External reference